Source: AJMC
Zachary Bloomgarden, MD; Robert Gabbay, MD, PhD, FACP; Silvio Inzucchi, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, provide additional insight on clinical data and the management of patients with diabetes at risk for cardiovascular events, and consider how the costs of emerging agents affect payers’ decisions regarding coverage for therapy.
